Middle-East and Africa Alpha-Glucosidase Inhibitors Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

Middle-East and Africa Alpha-Glucosidase Inhibitors Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

The Middle-East and Africa Alpha-Glucosidase Inhibitors Market is expected to register a CAGR greater than 3.5% over the forecast period.

COVID-19 and diabetes have a significant impact on public health in the Middle East and Africa, as well as elsewhere. Diabetes has been linked to an increased risk of fatal infections and severe infections in COVID-19 patients. Because diabetes is one of the most common health problems in the Middle East and Africa, the current study focused on understanding the epidemiology of COVID-19 in diabetics and the strategies put in place by governments to mitigate its impact. In light of the importance and necessity of the epidemic, countries in the Middle East and Africa have implemented a number of preventative and control measures.

The Middle East and African region have witnessed an alarming increase in the prevalence of diabetes, in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels.

This is driving the demand for Alpha-Glucosidase Inhibitors Market in Middle-East and Africa, thereby driving the market in focus during the forecast period.

Key Market TrendsRising Diabetes Prevalence in Middle-East and Africa Region

Type 1 diabetes accounts for approximately 10% of diabetes cases in the Middle East and Africa, while Type 2 diabetes accounts for 90%. Type 1 diabetes patients must take insulin for the rest of their lives, while also eating a healthy diet and exercising regularly. Type 2 diabetes patients must eat healthily, stay physically active, and have regular blood glucose tests. They may also need to take oral medication and insulin to keep their blood glucose levels under control. Diabetes has many complications, including diabetic ketoacidosis and non-ketotic hyperosmolar coma. Heart disease, stroke, kidney failure, foot ulcers, and eye damage are all serious long-term complications. Despite extensive research on COVID-19, only a few Middle Eastern and African countries have focused on the epidemiology of COVID-19 among diabetic patients and its implications. We emphasise the critical importance of conducting a thorough study to fully understand COVID-19 and its relationship to diabetes in order to develop and implement evidence-based initiatives and policies in the Middle East and Africa.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the Middle East and Africa Region.

Saudi Arabia and Egypt is Expected to Dominate the Middle-East and Africa Alpha-Glucosidase Inhibitors Market.

Diabetes is one of the mounting health problems the country is facing. Saudi is ranked among the top three in the Middle East and African countries with the highest prevalence of diabetes. The diabetes population in Saudi Arabia increased from 1.48 million in 2012 to 5.95 million in 2021 and is expected to reach more than 8 million by 2027. The type-1 diabetes population in the country is projected to reach more than 0.5 million by 2027 from 0.39 million in 2021.

Saudi Arabia is aiming to reduce the prevalence of the disease by 10% over the next decade. Several initiatives, including taxing sugary drinks, fitness initiatives, and focusing on preventative care, are being taken up by the government to stem the rising epidemic. The government’s focus on combating diabetes and the higher purchasing power of the people in the country may help the market for diabetes drugs, like insulin drugs, during the forecast period.

The Government has been working on plans and policies to control the outcomes of diabetes. For instance, Saudi Government, in July 2022, announced that Saudi Arabia has seen growing demand for quality healthcare services spurred by changes including an increasing and aging population, and a growing prevalence of lifestyle diseases such as diabetes and obesity. The government and private sector are both involved to work on healthcare entities, certifications, and regulations. The government is taking steps to have 100 percent of Saudi citizens covered by insurance and is working towards ensuring affordability, access, and quality digital healthcare and primary care with cost-effectiveness.

Owing to the aforementioned factors the market is expected to grow during the forecast period.

Competitive Landscape

The market studied is highly fragmented into many manufacturers like Bayer, SunPharma, Pfizer, and Takeda holding a presence in Middle-East and Africa.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.